Phase 1 Study of CS-1008 - Evaluation of Safety and Pharmacokinetics of CS-1008 in Japanese Patients With Solid Cancer
Latest Information Update: 25 May 2016
At a glance
- Drugs Tigatuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 25 May 2016 New trial record